← Leaderboards
Shiaw-Yih Lin
University Of Tx Md Anderson Can Ctr
$9,839,199
Attributed
$9,839,199
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,839,199 · 7
By mechanism
R01$9,760,937 · 6
F32$78,262 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Russell R Broaddus$6,374,452
- Rugang Zhang$23,913,209
- Ferdinandos Skoulidis$4,461,361
- Meera Nanjundan$2,006,869
- Melinda S. Yates$1,868,494
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMouse ModelTumorIn VivoResponseMutationDna DamageMediatingBaseGenomic InstabilityMalignant NeoplasmsSamplingProteinsAffectResistanceImmunotherapyEnzymesExhibitsDna BiosynthesisCombined Modality TherapyCytokineGenomicsTherapeutic EffectSignal Transduction
Grant awards (32)
RNase H2 is a novel therapeutic target in triple negative breast cancer$384,115
R01 · FY2025 · CA · contact PI
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer$369,404
R01 · FY2025 · CA · contact PI
RNase H2 is a novel therapeutic target in triple negative breast cancer$364,910
R01 · FY2024 · CA · contact PI
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer$350,935
R01 · FY2024 · CA · contact PI
RNase H2 is a novel therapeutic target in triple negative breast cancer$376,433
R01 · FY2023 · CA · contact PI
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer$362,016
R01 · FY2023 · CA · contact PI
RNase H2 is a novel therapeutic target in triple negative breast cancer$376,433
R01 · FY2022 · CA · contact PI
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer$362,016
R01 · FY2022 · CA · contact PI
RNase H2 is a novel therapeutic target in triple negative breast cancer$384,115
R01 · FY2021 · CA · contact PI
Signature-guided therapy for mismatch repair defective cancers$373,331
R01 · FY2021 · CA · contact PI
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer$369,404
R01 · FY2021 · CA · contact PI
Signature-guided therapy for mismatch repair defective cancers$373,331
R01 · FY2020 · CA · contact PI
Signature-guided therapy for mismatch repair defective cancers$362,131
R01 · FY2019 · CA · contact PI
Signature-guided therapy for mismatch repair defective cancers$373,331
R01 · FY2018 · CA · contact PI
Signature-guided therapy for mismatch repair defective cancers$373,331
R01 · FY2017 · CA · contact PI
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer$323,036
R01 · FY2017 · CA · contact PI
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer$323,036
R01 · FY2016 · CA · contact PI
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer$323,036
R01 · FY2015 · CA · contact PI
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer$319,345
R01 · FY2014 · CA · contact PI
Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer$323,036
R01 · FY2013 · CA · contact PI
Functional and Clinical Analysis of Rak in Breast Cancer Suppression$255,440
R01 · FY2011 · CA · contact PI
Functional and Clinical Analysis of Rak in Breast Cancer Suppression$263,340
R01 · FY2010 · CA · contact PI
Functional and Clinical Analysis of Rak in Breast Cancer Suppression$263,340
R01 · FY2009 · CA · contact PI
BRIT 1: Roles in Immortalization, Checkpoints and Cancer$252,809
R01 · FY2009 · CA · contact PI
Functional and Clinical Analysis of Rak in Breast Cancer Suppression$263,340
R01 · FY2008 · CA · contact PI
BRIT 1: Roles in Immortalization, Checkpoints and Cancer$252,809
R01 · FY2008 · CA · contact PI
Functional and Clinical Analysis of Rak in Breast Cancer Suppression$263,340
R01 · FY2007 · CA · contact PI
BRIT 1: Roles in Immortalization, Checkpoints and Cancer$252,809
R01 · FY2007 · CA · contact PI
BRIT 1: Roles in Immortalization, Checkpoints and Cancer$260,360
R01 · FY2006 · CA · contact PI
BRIT 1: Roles in Immortalization, Checkpoints and Cancer$266,625
R01 · FY2005 · CA
Chk2--Roles in Checkpoint and Breast Tumor Suppression$43,430
F32 · FY2003 · CA
Chk2--Roles in Checkpoint and Breast Tumor Suppression$34,832
F32 · FY2001 · CA